title: [Levosimendan].
authors.affiliation: Klinik III für Innere Medizin, Universität zu Köln.
authors.forename: G
authors.initials: G
authors.lastname: Michels
authors.forename: S
authors.initials: S
authors.lastname: Herzig
authors.forename: U C
authors.initials: UC
authors.lastname: Hoppe
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D002316:Cardiotonic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006835:Hydrazones / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D011724:Pyridazines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000077464:Simendan; D014665:Vasodilator Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D006835:Hydrazones; D010726:Phosphodiesterase Inhibitors; D011724:Pyridazines; D014665:Vasodilator Agents; D000077464:Simendan; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3